These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8687094)

  • 21. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
    el-A Helal T; Khalifa A; Kamel AS
    Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of HER2/neu status in Qatari women with breast carcinoma.
    Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
    Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients.
    Ferrero JM; Etienne MC; Formento JL; Francoual M; Rostagno P; Peyrottes I; Ettore F; Teissier E; Leblanc-Talent P; Namer M; Milano G
    Br J Cancer; 2000 Jan; 82(1):171-7. PubMed ID: 10638986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
    Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression.
    Parikh RR; Yang Q; Higgins SA; Haffty BG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):35-42. PubMed ID: 17855007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S-Phase fraction, p53, and HER-2/neu status as predictors of nodal metastasis in early vulvar cancer.
    Gordinier ME; Steinhoff MM; Hogan JW; Peipert JF; Gajewski WH; Falkenberry SS; Granai CO
    Gynecol Oncol; 1997 Nov; 67(2):200-2. PubMed ID: 9367708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma.
    Sebastiani V; Botti C; Di Tondo U; Visca P; Pizzuti L; Santeusanio G; Alo PL
    Anticancer Res; 2006; 26(4B):2983-7. PubMed ID: 16886624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
    Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
    Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
    Cabioglu N; Yazici MS; Arun B; Broglio KR; Hortobagyi GN; Price JE; Sahin A
    Clin Cancer Res; 2005 Aug; 11(16):5686-93. PubMed ID: 16115904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA.
    Zhu L; Kim K; Domenico DR; Appert HE; Howard JM
    J Surg Oncol; 1996 Feb; 61(2):100-5. PubMed ID: 8606540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?
    Chavez-MacGregor M; Gonzalez-Angulo AM
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):591-8. PubMed ID: 20020671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients.
    Wiltschke C; Kindas-Muegge I; Steininger A; Reiner A; Reiner G; Preis PN
    J Cancer Res Clin Oncol; 1994; 120(12):737-42. PubMed ID: 7798300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.